This book provides a comprehensive overview of the field of monoclonal antibodies through twenty-five articles by recognized experts in the field.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Part I. Introduction: 1. Past, present and future of recombinant antibodies G. Winter; Part II. Generation and Screening of Antibody Libraries: 2. Antibody libraries from naïve V gene sources G. Beste and D. Lowe; 3. Antibodies from IgM libraries V. Molkenthin and S. Knackmuss; Part III. Transgenic Human Antibody Repertoires: 4. The generation and screening of synthetic antibody libraries I. Klagge; 5. Therapeutic antibodies from xenoMouse transgenic mice A. Jakobovits; 6. Transgenic chimeric antibodies A. Murphy; Part IV. Humanised Antibodies: 7. Humanization of recombinant antibodies J. Saldanha; 8. Immunogenicity assessment of antibody therapeutics P. Stas, J. Pletinckx, Y. Gansemans, and I. Lasters; 9. In vitro screening for antibody immunogenicity F. Carr and M. Baker; Part V. Antibody Effector Function: 10. Mechanisms of tumour cell killing by therapeutic antibodies R. Stewart and C. Webster; 11. Optimization of Fc domains to enhance antibody therapeutics G. Lazar and A. Chamberlain; 12. Glycoengineered therapeutic antibodies P. Brünker, P. Sondermann, and P. Umana; Part VI. Arming Antibodies: 13. Monoclonal antibodies for the delivery of cytotoxic drugs D. King; 14. Immunotherapy with radioimmune conjugates C. Kousparou and A. Epenetos; 15. Immunotherapeutic antibody fusion proteins N. Courtenay-Luck and D. Jones; Part VII. Antibody Fragments: 16. Alternative antibody formats F. Le Gall and M. Little; 17. Single domain antibodies S. Muyldermans; 18. Engineering of non-CDR loops in immunoglobulin domains F. Rüker and G. Wozniak-Knopp; Part VIII. Antigen Binding Repertoires of Non-Immunoglobulin Proteins: 19. Alternative antibody scaffolds A. Plueckthun; Part IX. Prolongation of Serum Half Life: 20. Polymer fusions to increase antibody half lives: PEGylation and other modifications S. Heywood and D. Humphreys; 21. Extending antibody half-lives with albumin J. Andersen and I. Sandlie; Part X. Current Therapeutic Antibodies and Novel Developments: 22. A stem cell-based platform for the discovery and development of anti-tumor therapeutic antibodies to novel targets J. Mather, C. Fieger, T. Liang, K. King, J. Li, P. Young, C. Beltejar, B. Potts, M. Licea, and D. Loo; 23. Antibody directed enzyme prodrug therapy (ADEPT) H. Lowe, S. Sharma, and K. Bagshawe; 24. Immune privilege and tolerance - therapeutic antibody approaches D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H. Waldmann, and M. Rosenzweig; Part XI. Market Overview and Outlook: 25. Antibody therapeutics: business achievements and business outlook C. Bourrilly.
Part I. Introduction: 1. Past, present and future of recombinant antibodies G. Winter; Part II. Generation and Screening of Antibody Libraries: 2. Antibody libraries from naïve V gene sources G. Beste and D. Lowe; 3. Antibodies from IgM libraries V. Molkenthin and S. Knackmuss; Part III. Transgenic Human Antibody Repertoires: 4. The generation and screening of synthetic antibody libraries I. Klagge; 5. Therapeutic antibodies from xenoMouse transgenic mice A. Jakobovits; 6. Transgenic chimeric antibodies A. Murphy; Part IV. Humanised Antibodies: 7. Humanization of recombinant antibodies J. Saldanha; 8. Immunogenicity assessment of antibody therapeutics P. Stas, J. Pletinckx, Y. Gansemans, and I. Lasters; 9. In vitro screening for antibody immunogenicity F. Carr and M. Baker; Part V. Antibody Effector Function: 10. Mechanisms of tumour cell killing by therapeutic antibodies R. Stewart and C. Webster; 11. Optimization of Fc domains to enhance antibody therapeutics G. Lazar and A. Chamberlain; 12. Glycoengineered therapeutic antibodies P. Brünker, P. Sondermann, and P. Umana; Part VI. Arming Antibodies: 13. Monoclonal antibodies for the delivery of cytotoxic drugs D. King; 14. Immunotherapy with radioimmune conjugates C. Kousparou and A. Epenetos; 15. Immunotherapeutic antibody fusion proteins N. Courtenay-Luck and D. Jones; Part VII. Antibody Fragments: 16. Alternative antibody formats F. Le Gall and M. Little; 17. Single domain antibodies S. Muyldermans; 18. Engineering of non-CDR loops in immunoglobulin domains F. Rüker and G. Wozniak-Knopp; Part VIII. Antigen Binding Repertoires of Non-Immunoglobulin Proteins: 19. Alternative antibody scaffolds A. Plueckthun; Part IX. Prolongation of Serum Half Life: 20. Polymer fusions to increase antibody half lives: PEGylation and other modifications S. Heywood and D. Humphreys; 21. Extending antibody half-lives with albumin J. Andersen and I. Sandlie; Part X. Current Therapeutic Antibodies and Novel Developments: 22. A stem cell-based platform for the discovery and development of anti-tumor therapeutic antibodies to novel targets J. Mather, C. Fieger, T. Liang, K. King, J. Li, P. Young, C. Beltejar, B. Potts, M. Licea, and D. Loo; 23. Antibody directed enzyme prodrug therapy (ADEPT) H. Lowe, S. Sharma, and K. Bagshawe; 24. Immune privilege and tolerance - therapeutic antibody approaches D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H. Waldmann, and M. Rosenzweig; Part XI. Market Overview and Outlook: 25. Antibody therapeutics: business achievements and business outlook C. Bourrilly.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
